Symbio Pharmaceuticals Ltd's next confirmed earnings release is scheduled for February 11, 2027.
| Earnings Date | 2/11/2027 |
As of September 30, 2026, Symbio Pharmaceuticals Ltd has 80.21M shares outstanding.
| Shares Outstanding | 80.21M |
As of September 30, 2026, Symbio Pharmaceuticals Ltd maintains a current ratio of 0.40, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -61.74, indicating conservative leverage, while an interest coverage ratio of -123.32 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.40 |
| Quick Ratio | 0.11 |
| Debt / Equity | -61.74 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | -123.32 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -220.97, reflecting losses generated across the asset base. The company generates approximately 73,954.19 in revenue per employee across its workforce of 91.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.31 indicates how many times Symbio Pharmaceuticals Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -220.97 |
| Revenue Per Employee | 73,954.19 |
| Employee Count | 91.00 |
| Inventory Turnover | 1.31 |
Over the twelve months ended September 30, 2026, Symbio Pharmaceuticals Ltd recorded 272,221.16 in income tax expense. The company reported a pretax loss of -38.43M and -38.71M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 272,221.16 |
As of the close on November 5, 2026, Symbio Pharmaceuticals Ltd's stock has declined approximately 45.41% over the past 52 weeks.
| 52-Week Price Change | -45.41% |
Over the twelve months ended September 30, 2026, Symbio Pharmaceuticals Ltd generated 6.73M in revenue and converted that into -38.71M in net income, yielding earnings per share of -0.55. EBITDA reached -37.95M, while operating income came in at -37.95M.
| Revenue | 6.73M |
| Gross Profit | 4.95M |
| Operating Income | -37.95M |
| Pretax Income | -38.43M |
| Net Income | -38.71M |
| EBITDA | -37.95M |
| EBIT | -37.95M |
| Earnings Per Share (EPS) | -0.55 |
As of September 30, 2026, Symbio Pharmaceuticals Ltd holds 1.61M in cash and equivalents against 5.08M in total debt, resulting in a net debt position of 3.47M. Total book value stands at -8.23M, with working capital of -8.46M providing operational flexibility.
| Cash & Cash Equivalents | 1.61M |
| Total Debt | 5.08M |
| Net Debt | 3.47M |
| Equity (Book Value) | -8.23M |
| Book Value Per Share | -0.10 |
| Working Capital | -8.46M |
Over the twelve months ended September 30, 2026, Symbio Pharmaceuticals Ltd posted a gross margin of 73.48, reflecting its pricing power and cost economics. The operating margin of -563.97 and net profit margin of -575.15 provide insight into operational efficiency.
| Gross Margin | 73.48 |
| Operating Margin | -563.97 |
| Pretax Margin | -571.11 |
| Profit Margin | -575.15 |
| EBITDA Margin | -563.97 |
Symbio Pharmaceuticals Ltd's most recent stock split took place on October 29, 2019 with a 4:1 split ratio.
| Last Split Date | 10/29/2019 |
| Split Ratio | 4:1 |
Already premium?